Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Drug Class Could Take on Colon Cancer

April 26, 2011 8:07 am | News | Comments

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study has found.


Kuros Candidate Reduces Healing Time

April 26, 2011 8:04 am | News | Comments

Kuros Biosurgery AG, announced that KUR-113 met the primary efficacy endpoint in a 200 patient Phase 2b clinical trial designed to assess its efficacy and safety in open tibial shaft fracture patients.


FDA Approves DUEXIS for Arthritis

April 26, 2011 7:54 am | News | Comments

Horizon Pharma, Inc. announced that the U.S. Food and Drug Administration has approved DUEXIS, a novel tablet formulation containing a fixed-dose combination of ibuprofen and famotidine.


Positive Results in Remoxy Study

April 26, 2011 7:50 am | News | Comments

Pain Therapeutics Inc. reported clinical study results that may indicate its pain drug candidate Remoxy is more difficult to abuse than OxyContin. The company said patients with a history of abusing painkillers did not enjoy Remoxy as much as OxyContin.


J & J Awaits Deceptive Marketing Ruling

April 26, 2011 7:47 am | by Meg Kinnard | News | Comments

It's now up to a Spartanburg County judge to decide how much a Johnson & Johnson subsidiary should pay South Carolina for deceptive marketing of an antipsychotic drug. If the judge agrees with attorneys for the state, it could be in the billions of dollars.


Absorption Systems Publishes CellPort Study

April 26, 2011 7:44 am | News | Comments

Absorption Systems announced the results of another study demonstrating the power of the company’s CellPort Technologies to predict the potential for pharmacokinetic drug-drug interactions.


Protease Inhibitors

April 25, 2011 8:23 am | Product Releases | Comments

The ProteaseArrest family of protease inhibitor cocktails are unique ready-to-use liquid format cocktails that offer immediate >98% inhibition of harmful proteases.


3D Cell Culture

April 25, 2011 8:20 am | Product Releases | Comments

AMSBIO has announced the launch of Alvetex, a cell culture scaffold that enables genuine 3D cell culture to be grown routinely and cost-effectively.


Merck, Sanofi Team on Phase 3 Trial

April 25, 2011 8:13 am | News | Comments

Merck and Sanofi Pasteur announced the initiation of a Phase 3 clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.


Higher Losses for Pharmasset in 2Q

April 25, 2011 8:10 am | News | Comments

Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal second-quarter loss Monday on higher research and development costs. The company lost $19.9 million, or 55 cents per share, in the quarter ended March 31.


Drug Combo Provides Hope for Cystic Fibrosis Patients

April 25, 2011 8:02 am | News | Comments

An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.


Artificially Malaria Immunity Lasts Longer Than Natural Immunity

April 25, 2011 7:50 am | News | Comments

A new immunological technique, in which patients are infected with malaria at the same time as being treated with prophylactic chloroquinine drugs, can give immunity against re-infection for at least 2.5 years, much longer than for immunity acquired naturally.


Mylan Launches Generic Femara

April 25, 2011 7:42 am | News | Comments

Generic drugmaker Mylan Inc. said it has launched a generic version of Novartis' breast cancer treatment Femara. Mylan and Novartis settled a patent dispute over the drug in 2008.


FDA Approves First Meningococcal Vaccine for Young Children

April 25, 2011 7:40 am | News | Comments

The U.S. Food and Drug Administration approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.


FDA Posts Positive Review of Boceprevir

April 25, 2011 7:37 am | by Matthew Perrone | News | Comments

Federal health officials said a highly-anticipated drug to treat hepatitis C made by Merck appears to cure more patients in less time than established drugs that have been used for 20 years.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.